BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 26909802)

  • 1. Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases.
    Cadier B; Durand-Zaleski I; Thomas D; Chevreul K
    PLoS One; 2016; 11(2):e0148750. PubMed ID: 26909802
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost effectiveness of full coverage of the medical management of smoking cessation in France.
    Chevreul K; Cadier B; Durand-Zaleski I; Chan E; Thomas D
    Tob Control; 2014 May; 23(3):223-30. PubMed ID: 23197369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simulation-based estimates of effectiveness and cost-effectiveness of smoking cessation in patients with chronic obstructive pulmonary disease.
    Atsou K; Chouaid C; Hejblum G
    PLoS One; 2011; 6(9):e24870. PubMed ID: 21949774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Budgetary Impact Analysis of Reimbursement Varenicline for the Smoking-Cessation Treatment in Patients with Cardiovascular Diseases, Chronic Obstructive Pulmonary Disease or Type-2 Diabetes Mellitus: A National Health System Perspective.
    Cedillo S; Sicras-Mainar A; Jiménez-Ruiz CA; Fernández de Bobadilla J; Rejas-Gutiérrez J
    Eur Addict Res; 2017; 23(1):7-18. PubMed ID: 27794567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.
    Linden K; Jormanainen V; Linna M; Sintonen H; Wilson K; Kotomäki T
    Curr Med Res Opin; 2010 Mar; 26(3):549-60. PubMed ID: 20050814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cost-effectiveness analysis of a community pharmacist-based smoking cessation programme in Thailand.
    Thavorn K; Chaiyakunapruk N
    Tob Control; 2008 Jun; 17(3):177-82. PubMed ID: 18285385
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of varenicline versus existing smoking cessation strategies in Central America and the Caribbean using the BENESCO model.
    Lutz MA; Lovato P; Cuesta G
    Hosp Pract (1995); 2012 Feb; 40(1):24-34. PubMed ID: 22406880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
    Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
    Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-effectiveness model of smoking cessation based on a randomised controlled trial of varenicline versus placebo in patients with chronic obstructive pulmonary disease.
    Lock K; Wilson K; Murphy D; Riesco JA
    Expert Opin Pharmacother; 2011 Dec; 12(17):2613-26. PubMed ID: 22017336
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness and budget impact of the fixed-dose dual bronchodilator combination tiotropium-olodaterol for patients with COPD in the Netherlands.
    van Boven JF; Kocks JW; Postma MJ
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2191-2201. PubMed ID: 27703341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
    Schädlich PK; Brecht JG; Rangoonwala B; Huppertz E
    Pharmacoeconomics; 2004; 22(15):955-73. PubMed ID: 15449961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of primary prevention of cardiovascular diseases in mild hypertension: a scenario analysis for the Netherlands.
    Stevanović J; O'Prinsen AC; Verheggen BG; Schuiling-Veninga N; Postma MJ; Pechlivanoglou P
    Clin Ther; 2014 Mar; 36(3):368-84.e5. PubMed ID: 24534654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.
    Lutz MA; Lovato P; Cuesta G
    Hosp Pract (1995); 2012 Feb; 40(1):35-43. PubMed ID: 22406881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact and cost-effectiveness of integrating smoking cessation into lung cancer screening: a microsimulation model.
    Evans WK; Gauvreau CL; Flanagan WM; Memon S; Yong JHE; Goffin JR; Fitzgerald NR; Wolfson M; Miller AB
    CMAJ Open; 2020; 8(3):E585-E592. PubMed ID: 32963023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The long-term cost-effectiveness of varenicline (12-week standard course and 12 + 12-week extended course) vs. other smoking cessation strategies in Canada.
    von Wartburg M; Raymond V; Paradis PE
    Int J Clin Pract; 2014 May; 68(5):639-46. PubMed ID: 24472120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimated Budget Impact of Adopting the Affordable Care Act's Required Smoking Cessation Coverage on United States Healthcare Payers.
    Baker CL; Ferrufino CP; Bruno M; Kowal S
    Adv Ther; 2017 Jan; 34(1):156-170. PubMed ID: 27888437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Budgetary impact analysis on funding smoking-cessation drugs in patients with COPD in Spain.
    Jiménez-Ruiz CA; Solano-Reina S; Signes-Costa J; de Higes-Martinez E; Granda-Orive JI; Lorza-Blasco JJ; Riesco-Miranda JA; Altet-Gomez N; Barrueco M; Oyagüez I; Rejas J;
    Int J Chron Obstruct Pulmon Dis; 2015; 10():2027-36. PubMed ID: 26451100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling a budgetary impact analysis for funding drug-based smoking cessation therapies for patients with major depressive disorder in Spain.
    Rejas-Gutiérrez J; Bruguera E; Cedillo S
    Eur Psychiatry; 2017 Sep; 45():41-49. PubMed ID: 28728094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating a collaborative smoking cessation intervention in primary care (ENTER): study protocol for a cluster-randomized controlled trial.
    Härter M; Bartsch AL; Egger N; König HH; Kriston L; Schulz H; Tiemann M; Brütt AL; Buchholz A
    Trials; 2015 Oct; 16():447. PubMed ID: 26452466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.